#lung cancer staging 2018

[wouldvelovedmewheniwassoft]

help keep a queer disabled system couple from breaking NC with my rapist ❤️‍🩹

(CW: parental abuse/familial trauma, death from cancer, alcoholism, domestic violence, homelessness, sui + hospitalization, incest/rape, victim-blaming, abandonment + gaslighting by a toxic friend, harassment involving police, disordered eating)

please don't tag my post. proof of situation provided in imgur album.

i've held off on publicly asking for help beforehand, as i know there are many people in more dire circumstances right now. but i'm at a point where it's absolutely necessary.

i moved out of state to live with my partner system (we both have DID) in March of this year. we already planned to live together, but circumstances forced me to escape and go NC (no contact) with my remaining family for my safety.

i lived in my childhood home for my whole life until this year. my parents and extended family have always been abusive, but things escalated after my mom passed from Stage 4 lung cancer. my father started deteriorating after her diagnosis in 2018, and since her death in 2022, our relationship is no longer salvageable.

his alcoholism worsened significantly, resulting in multiple instances of him driving home drunk, collapsing, and almost being charged with a DUI. he hasn't hit me since i was 13, but he's acted domestically violent by slamming and hitting things whenever i've angered him. he threatened me with homelessness twice for being suicidal (once after a four day hospitalization, once after an attempted overdose), knowing full well i had no resources at the time and would've ended up on the streets. i attempted to escape last year, but my paternal aunt purposefully sabotaged it, forcing me to stay in an unsafe situation and suffer quietly. my mother's family abandoned me in 2020, and they no longer accept me (specifically for being queer/trans, disabled, and a vocal leftist), so they wouldn't help even if i wanted to resume contact.

it took over a year to move out due to my father controlling every aspect of my life with the justification of me being disabled. i tried to get his blessing for me to move in with my partner; but he refused to let me leave him, and he made it clear his disapproval of my relationship was because he didn't want me to have any autonomy outside of him.

the breaking point came after three days of nonstop verbal and emotional/mental abuse from him over an argument he started; everything culminated in him raping me while i was incapacitated. both my best friend of three years and their partner offered for me to crash at their apartment while my partner planned to get me. they also escorted me to a sexual assault center in my state to get a rape kit done.

i burned nearly every bridge in the process, as the people who could help me sided with him. but i didn't anticipate my friends to abandon me, too. they spent my last three days with them coercing me into changing my escape plan and dismissing my visible distress at how doing so would jeopardize my safety. less than 12 hours before we left, my best friend abandoned me via text, saying they'd refuse to help me if i didn't get police involved. anything i said in response resulted in gaslighting from them, mainly using therapy speak of "boundaries" and "triggers" to justify their actions. i cut contact with them after my partner told me they planned to drop me from the start (they told my partner this in a phone call while i was out) and discovering a cruel vague post they made after i last texted them. the last time i ever reached out was to send them money to get through their own situation.

since then, my partner and i have struggled financially. they're currently one write-up away from being fired, and their supervisor has always been volatile, so confronting him or going to anyone else at their job will do nothing. they've gotten help from their grandparents, but they're similarly abusive and unaccepting of them for the same reasons, so it hurts them to beg them even if they're unable to go NC right now.

i'm unable to reapply for disability, and previously lucrative sources of passive income have currently dried up. i'm waiting for orientation to be scheduled so i can start my new job, but we've financially suffered in the meantime. my account was charged off, and i only just now paid off a month's worth of PayPal debt; most of the debt came from paying off medical bills after i was injured in late April (currently contemplating pursuing legal compensation but nothing's set in stone).

i had to break NC twice for my father to help, but it's been triggering both times. i had to block his number before due to him harassing me via call/text, and he made me talk to police twice by falsely reporting me missing.

i cannot risk breaking NC again if my future job falls through or my partner loses theirs. we both had to skip meals several times within the past month to keep from buying food, so it's gotten scary already.

anything you can send helps. if you're unable to, PLEASE share this wherever you can. i also do writing commissions, so DM me to know my rates and what i'm willing to write.

ca | pp | vm

imgur album

(edit 6/18/24: created a new imgur album link; had no idea why the first one was inaccessible, but hopefully this is better formatted and contains additional context)

[longlistshort]

This mural was created by Lara Nguyen in 2016 for The Refinery in Asheville, North Carolina. The local artist and teacher’s design was chosen for the building by the Asheville Area Arts Council.

From a Mountain Xpress article about the work-

Bowerbirds and butterflies decorate the building’s facade. Nguyen considers the former “the artists of the bird world.” Each year, for up to six months, the male bowerbird will spend its days building arches made of straw. He will then gather brightly colored objects and place them outside the construction in order to attract mates.

“They perform,” says Nguyen. “They use the hole [of the arch] as a stage. … They’re also great mimickers and singers. I thought that was interesting. They’re like actors, performance artists, builders, makers, collectors, [and] in some way they’re painters. They pick certain colors and situate them.”

Nguyen saw the creature as a perfect symbol for The Refinery Creator Space. She lists off the various types of artists (painters, photographers, sculptors, filmmakers, fiber artists…), in addition to the art-based organizations (Asheville Darkroom, Asheville Makers, The Bright Angle, Local Cloth and Mechanical Eye Microcinema) that now call the space their home. She views her mural, with its bright colors and visual appeal, as a way to help facilitate traffic; a way to intrigue the public to step inside and support the arts.

More recently, Nguyen contributed work to the 2023 annual ArtFields event in Lake City, South Carolina. The two pieces are from her series “Letters to My Children”.

Her statement about these works-

“Strong Arms” & “Keep Going” are from a series entitled “Letters to My Children.” I was diagnosed with uterine leiomyosarcoma in July 2018 when my kids, Atticus and Moon, were 7 & 9 years old. In January 2020, my lung collapsed and I underwent a lobectomy. Now with a stage 4 cancer diagnosis I have found myself up at all hours worrying about dying before my kids are grown. When I couldn’t sleep, I wrote letters to them, recording their favorite recipes and my fondest memories of them for them. In 2021, I decided to share my writing with them instead of saving all this pondering in a box for later. Making and sharing this work has allowed us to cry and grieve together, which, in turn, has opened up space to truly be honest and present for one another while we are all still alive. With my children’s permission, I present slices of difficult conversations we have had to a wider audience in hopes of easing any load the viewer might be carrying on their own personal journey.

[bodgei]

In the summer of 2017 I took my husband to a comic convention. It was in Boston (where we lived early in our relationship and where our kids and grandkids still live)

He had a great time and was looking forward to us having a booth there someday, selling my writing.

In June of 2018 he was diagnosed with stage 4 lung cancer and died in November.

He made me promise that I would write something that I can sell at comicon.

I still find it almost impossible to write.

Someday though.

A co-worker of mine was standing outside with me during a break from customers to share a cigarette with me, and told me about how he had lost his brother that he was close with some years ago. He told me about how they used to be in a band together with some friends, and how ever since he'd died, he hadn't played any music because he'd been too scared and anxious. I told him about how I'd lost my brother to suicide some years ago.

I went home and pulled out an old tiny wooden box my brother had given me before he'd died. I'd been using it to store guitar picks I'd collected over the years, including one guitar pick that used to be his. I haven't played the guitar since he'd died, my hands are too small to play some of the chords, so I play bass and piano instead.

I went to work the next day and gifted my brothers old guitar pick to my co-worker. I told him that it'd been sitting in a box for ten years unused, and would probably sit there for longer if I kept it there. Told him that I thought he deserved to have it, because I bet he could put it to better use than I ever would. Told him I didn't feel like it was coincidence that me and him would cross paths with each other in our lives, and that it seemed suiting that we had these similar experiences but split in two halves. That somehow, I felt like he was meant to have the guitar pick. I told him that I knew he'd not played guitar since his brother died, but that if he ever decided to play again one of these days, maybe he'd be able to honor both of our brothers by using that guitar pick.

He almost cried. He thanked me. Then he went home that night and for the first time in years he played the guitar.

I don't know what the meaning of life is or what my purpose is, but I do believe that love and human connection is one of the most important things in life. It's finding ways to tell strangers you love them and share experiences with others. I think it's all just about love.

[marketingreportz]

Companion Diagnostics Market - Forecast(2024 - 2030)

 Companion Diagnostic Market Overview:

The Harvard University, while addressing the risk associated with reactions of new drugs prescription, has stated some overwhelming facts. According to their findings, even properly prescribed drugs causes about 1.9 million hospitalizations a year and about 128,000 people die from drugs prescribed to them.[1] Such epidemic condition is being tailgated by the need of safe and effective and specific use of the drug. Owing to such demands, companion diagnostic drug market is poised for exponential growth. Companion diagnostics is an in-vitro diagnostic tool that assists physicians in optimizing treatment decisions for their patients and is crucial for myriad of cancer and other therapies. Riding on the back of economic burden of global healthcare and with abundant potential to restrict the liability, companion diagnostic market size is estimated to be $2,950 million as of 2018.

Inquiry Before Buying

Companion Diagnostic Market Outlook:

Companion diagnostic (CDx) is a diagnostic test used as an associate to a therapeutic drug to regulate its applicability to an individual person. It involves multiple monitoring methods including immunohistochemistry (IHC), polymerase chain Reaction (PCR), in-situ hybridization (ISH), real-time PCR (RT-PCR), and gene sequencing. The companion diagnostics uses technologies such as molecular biology technique, drug and diagnostic technology, and oncology therapy for the treatment of colorectal cancer, breast cancer, and other chronic diseases.

 An acute analysis of the region-wise companion diagnostic market share concluded with reckoning North America as the most lucrative market for CDx. This region with cutting-edge healthcare technology in the United States and Canada generates 41% of the global companion diagnostic market demand for alarming need for cancer diagnosis and treatment. According to the American Cancer Society, prostate cancer is the most common cancer among males (19%), followed by lung (14%) and colorectal (9%) cancers and among females, breast (30%), lung (12%), and colorectal (8%) cancers are the most common. Increasing instances of cancer along with neurological disorders, infectious diseases, Hepatitis A is augmenting the North American companion diagnostic market.

Companion diagnostic market with abundant potential as an effective tool for personalized medicine has found a tremendous scope of application in pharmaceuticals, laboratories, research institutes and hospitals. Hospital as an end-user industry is the leading segment progressing with an application CAGR of 12.5% going through 2025. Hospitalized patients account for a total of 2.74 million serious adverse drug reactions. Each CDx test is specifically designed to be corresponding with an exact drug. Such tests can also save significant hospital expenditure by targeting specific patients with the most effective therapy.

Request Sample

 Companion Diagnostic Market Trends and Growth Drivers:

·         The necessity for personalized therapeutics for the cumulative geriatrics population and the increasing figure of diagnostics centers in both the developed and developing economies is predominant to determine profits in the global companion diagnostics market.

·         FDA had issued "Guidance for Industry: In Vitro Companion Diagnostic Devices," to assist syndicates recognize the necessity for companion diagnostics at an initial stage in the drug development procedure and to strategize for co-development of the drug and companion diagnostic test.

 On July 15, 2016, FDA introduced the draft regulation, "Principles for Co-development of an In Vitro Companion Diagnostic Device with a Therapeutic Product." This guidance text is envisioned to be a practical guide to support therapeutic product promoters and IVD sponsors in evolving a therapeutic product and an associated IVD companion diagnostic. The scientific progressions in the in-situ hybridization and automated silver-enhanced in-situ hybridization (SISH) for the monitoring of genes is trending in the global companion diagnostics market.

Schedule a Call

 Companion Diagnostic Market Players Perspective:

Some of the key players influencing the global market are:-  Abbott Laboratories, Agilent Technologies, biomerieux, Bio-Genex Laboratories, Danaher Corporation, GE Healthcare, Myriad Genetics, Inc., QIAGEN N.V., R-Biopharm AG, and Roche Diagnostics.

In April 2017, Abbott acquired Alere for a new price of about $5.3 billion. Alere is the global leader in point of care diagnostics focused on the areas of infectious disease, molecular, cardiometabolic and toxicology. The collective business will offer the biggest point of care menu of infectious disease, molecular, cardiometabolic and toxicology testing. Abbott's platforms will be expanded to comprise benchtop and rapid strip tests.

Buy Now

 Companion Diagnostic Market Research Scope:

The base year of the study is 2018, with forecast done up to 2025. The study presents a thorough analysis of the competitive landscape, taking into account the market shares of the leading companies. It also provides information on unit shipments. These provide the key market participants with the necessary business intelligence and help them understand the future of the companion diagnostic market. The assessment includes the forecast, an overview of the competitive structure, the market shares of the competitors, as well as the market trends, market demands, market drivers, market challenges, and product analysis. The market drivers and restraints have been assessed to fathom their impact over the forecast period. This report further identifies the key opportunities for growth while also detailing the key challenges and possible threats. The key areas of focus include the various diagnostics in companion diagnostic market, and their specific advantages.

[industryinsightsandanalysis]

U.S. Hospice Market: Trends, Drivers, and Future Outlook

The U.S. hospice marketis poised for significant growth, with an anticipated compound annual growth rate (CAGR) of around 8% during the forecast period. Hospice care, a specialized type of care for patients in the terminal phase of their life, emphasizes comfort and quality of life for patients and their families. The burgeoning demand for hospice care is driven by several factors, including the aging population and the rising prevalence of chronic diseases. This article delves into the key market drivers, segmentation, geographic trends, and major players shaping the future of the U.S. hospice market.

Key Market Drivers

1. Aging Population:

The demographic shift towards an older population is one of the primary drivers of the hospice market. The United States is experiencing a significant increase in the geriatric population. According to the United Nations World Population Ageing 2019 report, the 65+ population in the U.S. was 53.3 million in 2019 and is projected to reach 84.8 million by 2050. Older adults are more prone to life-limiting illnesses, thereby increasing the demand for hospice care.

2. Prevalence of Chronic Diseases:

Chronic diseases such as cancer, cardiovascular diseases (CVD), chronic respiratory diseases, and chronic kidney diseases are on the rise. Nearly half of the U.S. adult population has some form of CVD, and by 2035, more than 135 million adults, or 45.1% of the population, are expected to have CVD. Similarly, cancer remains a leading cause of death, with the World Health Organization (WHO) reporting around 2.09 million cases of lung cancer globally in 2018. The rising incidence of these chronic conditions necessitates enhanced hospice care services.

3. Shift towards Home Care:

There is a growing preference for home-based hospice care among patients and families. Home care settings offer a comfortable and familiar environment, personalized care, and a cost-effective alternative to long-term hospital stays. The Centers for Disease Control and Prevention (CDC) reported an increase in the number of hospice care agencies from 4,300 in 2016 to 4,500 in 2018, reflecting this trend.

For a comprehensive analysis of the market drivers, visit: https://univdatos.com/report/u-s-hospice-market/

Market Segmentation

By Diagnosis:

The hospice market is segmented based on the diagnosis into cancer, cardiovascular diseases, chronic respiratory diseases, chronic kidney diseases, and others.

Cancer:

The cancer segment is expected to witness considerable growth due to the increasing number of cancer cases among the elderly population. Advancements in cancer treatments and surgeries further drive the need for hospice care to support patients during their final stages of life.

Cardiovascular Diseases:

The high prevalence of cardiovascular diseases contributes significantly to the hospice market, as patients with severe heart conditions often require end-of-life care.

By Provider:

The market is categorized by provider into hospitals & nursing homes, home care settings, and others.

Home Care Settings:

This segment is anticipated to grow substantially due to the preference for home-based care. Home hospice care allows patients to spend their final days in a familiar environment with their loved ones, supported by professional caregivers.

Geographic Trends

Geographically, the U.S. hospice market is analyzed across major states, including California, Texas, Florida, New York, and Pennsylvania.

California: California holds the largest market share due to its high number of healthcare facilities and treatment options. The states large and growing elderly population, combined with a high prevalence of chronic diseases, drives the demand for hospice care services. The presence of a significant number of hospitals and advanced medical infrastructure further bolsters the market in California.

For a sample report, visit:- https://univdatos.com/get-a-free-sample-form-php/?product_id=22835

Conclusion

The U.S. hospice market is set for robust growth, driven by the aging population, increasing prevalence of chronic diseases, and the shift towards home-based care. With advancements in healthcare and a growing emphasis on quality of life for terminally ill patients, the demand for hospice services is expected to rise significantly. Major market players are continually innovating to meet this demand, ensuring that patients receive compassionate and comprehensive end-of-life care.

Contact Us:

UnivDatos Market Insights

Email - contact@univdatos.com

Contact Number - +1 9782263411

Website -www.univdatos.com

[saumayatripathi]

Breaking Ground: The Rise of Anti-Cancer Manufacturers and Suppliers in India

In recent years, the global battle against cancer has intensified. With the alarming rise in cancer cases worldwide, the demand for effective anti-cancer drugs has surged exponentially. In India, where the burden of cancer is significant, the emergence of anti-cancer manufacturer in India has become pivotal in addressing this pressing healthcare need.

The Global Cancer Crisis Cancer, often dubbed as the "silent epidemic," continues to be one of the most formidable health challenges of the 21st century. According to the World Health Organization (WHO), cancer is the second leading cause of death globally, responsible for an estimated 9.6 million deaths in 2018 alone. Moreover, the incidence of cancer is projected to rise by 50% over the next two decades.

The Demand for Anti-Cancer Drugs As the prevalence of cancer escalates worldwide, the demand for anti-cancer drugs has reached unprecedented levels. These drugs play a pivotal role in various stages of cancer treatment, including chemotherapy, targeted therapy, immunotherapy, and hormonal therapy. However, ensuring access to affordable and high-quality anti-cancer medications remains a significant challenge, particularly in low- and middle-income countries like India.

Florencia Healthcare: Leading the Charge Amidst this healthcare landscape fraught with challenges, Florencia Healthcare has emerged as a beacon of hope. As a leading anti-cancer drugs manufacturer and supplier in India, Florencia Healthcare has been at the forefront of producing a wide array of high-quality medications to combat cancer effectively.

Innovative Solutions for a Global Crisis Florencia Healthcare's commitment to innovation and excellence has propelled it to the forefront of the industry. With state-of-the-art manufacturing facilities and a dedicated team of researchers, Florencia Healthcare is pioneering breakthroughs in anti-cancer drug development. Their comprehensive portfolio encompasses a diverse range of medications targeting various types of cancer, including breast cancer, lung cancer, prostate cancer, and leukaemia, among others.

Exporting Excellence Beyond catering to the domestic market, Florencia Healthcare has earned a reputation as a trusted exporter of anti-cancer drugs to countries worldwide. Through strategic partnerships and stringent quality control measures, the company ensures that its products adhere to international standards of safety, efficacy, and affordability.

Empowering Healthcare Access In addition to their commercial endeavours, Florencia Healthcare is deeply committed to advancing healthcare access and affordability. Through initiatives aimed at increasing awareness, providing patient assistance programs, and collaborating with healthcare institutions, the company endeavours to make life-saving anti-cancer medications accessible to all those in need.

Driving Economic Growth The rise of anti-cancer manufacturers and suppliers like Florencia Healthcare also holds immense potential for driving economic growth and innovation in India. By investing in research and development, infrastructure, and skilled manpower, these companies contribute significantly to the nation's pharmaceutical industry, positioning India as a global leader in healthcare innovation.

Conclusion As the global fight against cancer intensifies, the role of oncology manufacturers and exporters in India has never been more critical. With Florencia Healthcare leading the charge, the landscape of cancer treatment is poised for transformation. Through innovation, excellence, and a commitment to accessibility, companies like Florencia Healthcare are not only saving lives but also shaping the future of healthcare worldwide.

[euronoxxmedicalgroup]

VENUS/VENUS+ Series: Transforming Mammography for Accurate Breast Cancer Diagnosis

In recent years, machine learning (ML) has moved to the forefront of medical imaging research from hand-push manual seeder to auto-initialisation. It revolutionised the field by enabling more intelligent and self-reliant computer-aided diagnosis (CAD) systems. The transformation of ML methods has paved the way for more accurate and efficient medical image analysis.

Advancements in ML have significantly enhanced the learning ability of CAD (computer-aided diagnosis) systems, leading to the development of automated methods capable of leveraging deep feature learning and images. This has resulted in a paradigm shift in medical imaging, with ML algorithms playing a crucial role in improving diagnostic capabilities.

One of the key developments in ML in medical imaging research is the introducing of deep learning (DL) approaches. These approaches involve the use of deep neural networks to extract complex features from medical images, enabling more accurate and robust analysis. DL methods have shown remarkable success in a wide range of medical imaging tasks, including image segmentation, classification, and detection of abnormalities.

The integration of DL techniques with medical imaging has significantly improved the accuracy and efficiency of CAD systems. By leveraging deeper and more extensive representation approaches, DL algorithms can effectively learn complex patterns and relationships within medical images, leading to more reliable diagnostic outcomes.

Cancer as a Leading Cause of Female Deaths Worldwide!

Cancer surpasses diseases like tuberculosis and malaria in causing female deaths globally.

World Health Organization (WHO) reports (International Agency for Cancer Research [IARC] and American Cancer Society) 17.1 million new cancer cases worldwide in 2018.

WHO estimates cancer cases may increase to 27.5 million by 2040, with 16.3 million deaths expected.

Breast Cancer Among Leading Cancers in Women!

Breast cancer ranks among the top 4 cancers in women worldwide (along with lung, bowel, stomach, and prostate cancers).

Breast cancer accounts for 25% of all cancer cases in women, with 53% of cases in developing countries.

626,700 deaths from breast cancer were reported in 2018.

Global Trends in Breast Cancer Deaths!

Breast cancer is a leading cause of cancer deaths among women in developing countries.

In developed countries, it is the second leading cause of cancer deaths after lung cancer.

Research and Risk Factors

Research indicates various factors such as hormonal, lifestyle, and environmental changes contribute to breast cancer risk.

Understanding the origins and risk factors is crucial for early detection and effective treatment of breast cancer.

The Vital Role of VENUS and VENUS+ Mammography Series in Medical Imaging Research!

The VENUS and VENUS+ mammography series have emerged as highly advisable techniques for identifying breast cancer. These advanced mammography systems have revolutionised the field of breast cancer detection by providing more precise and unparalleled precision results.

One significant advantage of these systems is that they expose the breast to much lower doses of radiation compared to devices used in the past, making them safer for patients.

Mammography has become a reliable tool for breast cancer screening and early detection. With its ability to capture detailed images of the breast tissue, mammography has greatly contributed to the identification of abnormalities, even in their early stages. It plays a crucial role in identifying potential breast cancer cases before symptoms become apparent, improving the chances of early intervention and successful treatment.

When using the VENUS and VENUS+ mammography systems, mammograms are acquired from two different views for each breast: craniocaudal (CC) and mediolateral oblique (MLO) views.

This multi-dimensional approach allows healthcare professionals to thoroughly assess breast tissue and identify potential abnormalities from different angles. The combination of these views offers a comprehensive evaluation of breast health, aiding in the early detection and diagnosis of breast cancer.

As technology goes on at a rapid phase, mammography systems like VENUS and VENUS+ will probably further improve breast detection abnormalities.

These systems allow for more accurate and reliable screening, helping to save lives by detecting breast cancer at its earliest stages. With their ability to minimise radiation exposure and provide detailed imaging, VENUS and VENUS+ mammography series stand as some of the most suitable techniques for detecting breast cancer in the modern healthcare landscape.

In ML technology applications of healthcare, particularly in the fight against breast cancer, the screening for early cancer cell detection, the importance of early and accurate diagnosis cannot be overstated. EuroNoxx Medical Group stands at the forefront of this battle with its innovative VENUS and VENUS+ mammography series. 

These Deep-learning Advanced imaging techniques combining AI are more than just medical equipment; they are lifelines that offer hope, comfort, and the promise of a healthier future for countless individuals.

The Human Touch Behind VENUS/VENUS+ Technology!

At the heart of the VENUS/VENUS+ series is a deep understanding of the patient and physician experience. For instance, the digital display and user-friendly interfaces of these machines are designed not just for the sake of technological advancement but to ensure a smoother, more comfortable diagnostic procedure. This focus on patient comfort is critical in encouraging more women to undergo mammograms, thereby facilitating the earlier detection of breast cancer.

Stories of Hope and Healing

Consider the story of Sarah, a 45-year-old teacher who was apprehensive about getting her first mammogram because of fears of discomfort and radiation exposure. Her experience with the VENUS+ system changed her perspective entirely. 

The quick and comfortable procedure, coupled with the compassionate care of the radiology team, transformed her anxiety into relief. Sarah's story is a testament to how EuroNoxx's technology, with its emphasis on patient comfort, can play a crucial role in early cancer detection.

 A Platform for Discussion!

We understand that the topic of mammograms can evoke a range of emotions and questions. That's why we encourage our readers to share their thoughts and concerns. What are your biggest questions about mammography? Let's start a conversation that demystifies the process and addresses your worries head-on.

Cutting-Edge Research and Recognition!

The latest advancements in mammography technology underscore our commitment to innovation. EuroNoxx's medical equipment, Medical Devices, Hospital Equipment, Surgical Instruments, Diagnostic Instruments, Patient Monitoring, and Laboratory equipment are designed to reflect and incorporate these breakthroughs.

We ensure that patients receive the most advanced care available. Moreover, our dedication to excellence has been recognised in the industry, with numerous awards underscoring our contributions to healthcare.

Conclusion

The VENUS/VENUS+ series of mammograms expose the breast to much lower levels of radiation than previous devices. EuroNoxx Medical offers the most advanced Computer-aided diagnosis (CAD) medical equipment; it represents a ray of hope for early breast cancer detection. By focusing on the benefits these technologies bring to patients, sharing real-life success stories, and engaging with the latest research and developments in Diagnostic Instruments, Patient Monitoring and cancer rehabilitation equipment supplies. 

EuroNoxx Medical is making a significant impact in the healthcare community. Join us in recognising the power of innovation and compassion in the fight against breast cancer.

[novaglobalhealthcare]

Recent FDA-Approved Cancer Treatments and Therapies

Tisagenlecleucel (Kymriah) is the first personalized gene therapy in the United States for:

Children and adults with relapsed/refractory B-cell acute lymphoblastic leukemia (2017.)

Adults with relapsed and refractory aggressive B-cell lymphoma (2018.)

Adults with relapsed/refractory follicular lymphoma (2022.)

Tocilizumab (Actemra) treats side effects from cancer immunotherapy (2017.)

Olapirib (Lynparza) targets BRCA-mutated refractory ovarian cancer and metastatic breast cancer (2018) and early-stage breast cancer with BRCA1/2 mutations (2022.)

Iobenguane I 131 (Azedra) is the first and only treatment option for adults and children with advanced and inoperable pheochromocytomas and paragangliomas (2018.)

Gilteritinib (Xospata) is the first drug of its kind for relapsed or refractory FLT3-mutated acute myeloid leukemia (2018.)

Transoral Robotic Surgery (TORS) was approved as a technology for operating on head and neck cancers (2019.)

Selinexor (Xpovio) is the first treatment of its kind for relapsed/refractory multiple myeloma (2019.)

Entrectinib (Rozlytrek) targets NTRK-mutated cancers in children and adults and ROS1-mutated non-small-cell lung cancers in adults (2020.)

Fluoroestradiol F 18 (Cerianna) enables visual detection of recurrent breast cancer by PET scan (2020.)

Belantamab mafodotin-blmf (Blenrep) is the first antibody – drug conjugate that selectively targets and kills myeloma cells to treat relapsed/refractory multiple myeloma (2020.)

Crizotinib (Xalkori) treats relapsed/refractory ALK-mutated systemic anaplastic large-cell lymphoma as well as inflammatory ALK-mutated myofibroblastic tumors in children and young adults (2021-22.)

Belzutifan (Welirig) is the first therapy of its kind for treating von Hippel – Lindau disease-associated tumors, such as renal cell carcinoma, central nervous system hemangioblastomas and pancreatic neuroendocrine tumors (2021.)

Cabozantinib (Cabometyx) treats refractory differentiated thyroid cancer in children and adults (2021.)

Pafolacianine (Cytalux) is the first FDA-approved substance to illuminate ovarian cancer (2021) and lung cancer (2022) lesions during surgery.

Teclistamab-cqvy (Tecvayli) is the first bispecific T cell engager antibody for the treatment of patients with relapsed or refractory multiple myeloma (2022.)

Mosunetuzumab-axgb (Lunsumio) is a bispecific CD20-directed CD3 T-cell engager indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy (2022.)

[gosomewherefindyourself]

Hurts (But It Goes Away)

It's been a very long time since I've graced the feed of either one of my tumblr's. It kind of feels like visiting the catacombs of my past but with the knowledge of all that I've become since I last wrote words here.

So much has happened since 2015, 2016, 2017, and 2018. I've gone through a lot more introspection, heartbreak, grief, personal development, friendships, joy, laughter, tears, etc. etc. etc.

What brings me here today is a desire to write again. A desire to put down my thoughts and feelings and record them for future Holly to check back in at another stage of her life. In the past, what drove me to write was an inexplicable need for connection and understanding. I felt so lost and misunderstood by everyone, including myself. I put my words on the page with hope that someone, somewhere, would read it, understand me, love me, and help me understand/love myself. What brings me here today is not the same intrinsic need for understanding. Instead, its me coming back to say I found me. I understand me. I love me.

As mentioned, A LOT has happened in the last few years. To attempt to sum it up, I spent a chunk of it in a deep grief morning the loss of my grandmother, the woman who I idolized, cherished, and held above all other humans in my life. My heart shattered when I lost her and a few pieces of me died right along with her. Her cancer was what brought me back early from the Peace Corps. She had stage 3 lung cancer and nothing else mattered. When I came home it became a group effort to get her better, to ensure her cancer knew how special she was to our family, to me. It seemed to work for a bit, she went into remission after a few months. She was better. I moved back to LA to jump start a career I had put on hold. The cancer didn't care. It came back and took her shortly after. I have such distinct memories of my grief before losing her. Realizing there was nothing we could do. Realizing I had lied to myself for years, telling myself over and over she would live forever. She would live long enough to see me get married, have a child, a career, and have a life she would be proud of. Have you ever been in a position where you are pleading to the universe for an outcome you know will never happen? It's desperate. It's ugly. It's raw.

I spent a decent chunk of time crying to Taylor Swift's "Soon You'll Get Better" song. It put everything into words that I experienced, the desperation and rawness of begging for an outcome you know won't come. You grieve for the pain your loved one is going through and you also selfishly mourn your impending loss. "Ooh-ah, Soon, you'll get better. Ooh-ah, Soon, you'll get better. Ooh-ah, You'll get better soon. Because you have to. And I hate to make this all about me, but who am I supposed to talk to? What am I supposed to do if there's no you?" I still feel this deep in my bones.

I spent the next two years in a depressing fog. I entered a grief support group, started seeing a therapist, and threw myself into my career. Work had always been a comfort of mine because it was something I could control. As a kid when things were rough at home, I longed for the hours spent in the classroom. Getting good grades and ultimately earning approval from the adults in my life in the only way I knew how. When I was bullied throughout middle school, I told myself it was all temporary and one day I'd make my life successful with a great career and life. Here was my chance. I lost all control I thought I had in this life. The most important person was taken from me and all I could do was hold onto the one thing that got me through my childhood. So I dove in and held nothing back.

The universe seemed to align with my plan. Enter the global pandemic more commonly known as Covid-19. Everyone was forced to isolate inside their own homes. Work, other than essential workers, was also moved to our homes. I was PREPARED for this. As a Peace Corps volunteer, I had a lot of experience isolating alone but this time I had electricity, running water, the internet, amazon, and an excuse to not socialize if I didn't want to... and let me tell you I didn't want to.

I spent my days working, reading, working, working out, working, watching tv, working, occasionally seeing friends, working, gardening, walking, oh and working. I was great at lockdown and it paid off. I moved up in my career and got the validation I spent most of my life striving for.

Post lockdown- I continued to ride that same train. Everyone else was focused on their own path and for once in my life, I wasn't focused on theirs either (the life of a CODA). I couldn't be. I was still drowning in my grief and honed in on this "successful life" I waited my whole life for. I don't know... I think I felt if I achieved "success" in my career, all of my problems would be solved. I would finally find myself, understand myself, and be whole.

Insert the biggest LOL here.

The next two years were filled with a lot of fulfillment through work. I loved my job, loved my coworkers, loved the trust and respect that came with it until I didn't anymore. It didn't happen overnight, and it definitely didn't just happen because something shifted in me... There were some external factors that showed me more about the "successful life" I thought I wanted and it ultimately turned out to be a hard and challenging life lesson. I'm not ready to lay all of that out there for public consumption. Just know that this was my second largest earth shattering heartbreak since 2019.

Fall of 2022 I went on a 3 week roadtrip to attempt to put myself back together. I was even more lost. I didn't have the one beacon I held onto my ENTIRE life anymore. Success didn't look like the success I cared to hold on to anymore, not when it came with all of the baggage I wanted no part of. Not only did I lose faith in the one thing guiding me most of my life, I lost faith in humanity. This shit has the ability to bring anyone to a point of questioning everything.

I think it's important to share here that most of my life I lived in a very black and white mindset. Do/Be good, receive good. Do/be bad, receive bad. I naturally believe the best in people and situations. If shit is rough, it just means that this is not meant for you and there's better things out there. The situation I found myself in really challenged that way of thinking. I thought I was doing good... but I was receiving bad. I attempted to right the bad and still received bad. I questioned myself a lot. Was I a terrible person?

Going back to what I mentioned at the beginning... I grew up feeling so lost, empty, and misunderstood but I ALWAYS believed that I was good... I yearned for someone else to see that goodness in me too. Now? Now I questioned that goodness. Was I ever good? Was I just lying to myself for all those years? Did I create this martyr persona but deep down I was just innately bad? As you can see, my shit was rocked. I was completely thrown off my axis.

The roadtrip helped me create space between me and the "bad" I left behind in LA. I was able to come back to myself, "coming back together, different but the same." I gave myself a rough timeline to execute a new plan to get out of LA and get out of a career driven mindset. I looked around and was so confused on how I lost my sense of adventure and how I gained a singular focus on career success. It was an absolute mindfuck. I was going to start carving out time for a personal life again. Making space for things I wanted to do because I WANTED TO DO THEM. This happened, it was great. But something else happened to... I was sucked back into the false sense of safety and growth in my career. In hindsight, this was either a test from the universe that I failed... or it was one last lesson the universe was guiding me through to show me VERY CLEARLY that a life of happiness/fulfillment is not 100% built on the foundation of a career.

This time, though, I was ready. All of the trials and tribulations I had been through in my life (and the support of an amazing therapist) had prepared me to recognize my worth and let me tell you, I was worth a hell of a lot more than the shit stick I had been handed, yet again. The day I finally realized this self worth, was the day I drove my ass to the store to get my first load of boxes to move.

I haven't yet mentioned the wonderful people in my life, which I feel incredibly blessed to be surrounded by. There are many times when I pause to reflect on my life and the fact that I've changed so much. I used to look around me and focus on the negatives... But lately what shines above it all are all of the blessings I've received. My friends, my community, my family. Do you ever just have a moment where you look back and think... "when did that happen?" I think that often about my support system. How blessed am I, to be surrounded by people who see me, love me, and support me? Who have taught me to appreciate all of the work I've done to be where I am now. People who have forced me to pause and give myself credit, even when it feels cringe to do so (I just think of that scene in Barbie where the Barbies are thanking themselves for the awards they've won because they deserve it... This is the kind of energy I am talking about here). Like I did that... I created a community for myself that I KNOW I am very blessed to have. I created a community that 10 year old Holly would never have believed was possible. A community that 4 year old Holly deserved to have. A life that 16 year old Holly would be proud of.

I think this is the kind of success that is not widely talked about. The kind of success that should be honored and appreciated far more than the dollar amount in your bank account.

I moved to Denver in November in search of a personal life I can be proud of. A life where my career is secondary to the life I am building for myself. I aim to be intentional with how I spend my time and so far I am really enjoying the ability to embrace newness. New opportunities, new adventures, new pieces of myself I get to meet and grow as I allow myself to expand beyond the boxes I've either put in place myself, or allowed others to put in place for me (more on that at another time).

Lately I've been thinking about the person I want to be known for. A person who is known for being your biggest cheerleader. Someone who who loves securely, unconditionally and freely and doesn't allow anyone in their lives to feel they only deserve love/happiness/success if they stay neatly in their "box" or how they believe they should act/behave. Someone who radiates joy, positivity, and happiness in a healthy completely realistic humanly way. I want to be someone who makes others around them feel like they are capable of anything they set their mind to.

... to be continued.

Thank you for reading this far <3

[indiamedicaltourism]

Cervical Cancer Surgery in India

Cervical cancer originates in the cervix, which is the lowest part of the uterus that connects to the vagina. The fourth most common disease among women is cervical cancer. 2018 saw almost 570,000 women receive a diagnosis. The majority of cases of cervical cancer are associated with high-risk human papillomavirus (HPV) infection, which is responsible for 99% of cases. It's one of the most effectively treated cancers when detected and managed at an early stage. Two primary forms are recognized: adenocarcinomas (10–20%) and squamous cell carcinomas (80–90%). Cervical cancer is most commonly identified in people between the ages of 35 and 45, and in low- and middle-income countries. HIV-positive women are six times more likely to get the virus, placing them at a much greater risk.

Surgical Advancements: Revolutionary advancements in cervical cancer surgery have been made in India to maintain fertility and improve treatment results. These days, it's increasingly common to use procedures like radical trachelectomy and cone biopsy, which remove malignant tissue without damaging the uterus.

Developments in Radiation Therapy: The developments in radiation treatment for cervical cancer demonstrate India's dedication to remaining at the forefront of medical science. Brachytherapy and External Beam Radiation Therapy (EBRT) are now considered standard treatments because of their ability to precisely target malignant cells.

Customized Chemotherapy for Effective Outcomes: For the treatment of advanced cervical cancer, a combination of radiation therapy and low-dose chemotherapy is successful. India's medical experts carefully customize chemotherapy treatments based on the individual requirements of every patient. The addition of targeted therapy, which targets certain chemicals found in cancer cells, also improves cervical cancer treatment effectiveness.

Immunotherapy: In India, immunotherapy has become a potentially useful therapeutic option for cervical cancer. Immunotherapy provides a focused and individualized treatment by using the body's immune system to identify and eliminate cancer cells.

One of the most important factors in treating cervical cancer successfully is early diagnosis. India has remarkable survival rates because of its dedication to encouraging routine checkups and breakthroughs in treatment approaches. Early detection of cervical cancer can result in a five-year relative survival rate of over 90%, highlighting the profound impact of early and focused therapies. Cervical cancer treatment cost in India is between $3500 to $12000. When combined with top-notch facilities, the affordability of medical procedures makes India a desirable travel destination for patients looking for life-changing treatments. Prominent doctors in the treatment of cervical cancer may be found in India's best hospitals, such as Artemis Hospital, Indraprastha Apollo Hospitals, and Medanta - The Medicity. Leading interdisciplinary teams, surgeons like Praveen Kumar Garg, Ankur Bahl, and Sandeep Batra make sure that patients receive the best possible treatment.

Al Afiya Medi Tour is a leading medical tourism company in India. We are offer medical tourism services in India foreign patients. Some of the main countries are Bangladesh, South Africa, Uganda, Zambia, Namibia, Iraq, Kenya, Ethiopia, Nigeria, and so on. We provide free assistance for TURP surgery cost, lung cancer treatment, breast cancer surgery cost, stomach cancer treatment, ovarian cancer treatment cost, liver transplant cost, best hospital for heart valve replacement, liver cancer treatment cost, bone marrow transplant cost,prostate cancer treatment cost, arthroscopic surgery, best liver transplant hospital, brain tumor surgery cost in India, kidney transplant, liver cancer treatment, aplastic anemia treatment cost, best bone marrow hospital, acute lymphoblastic leukemia treatment cost etc.  If you are searching for free medical and healthcare consulting to find the best hospitals and top doctors and surgeons in India for any treatment then contact us- Alafiyameditour.com. Source: https://alafiyameditour1.blogspot.com/2024/01/cervical-cancer-surgery-in-india.html

[sandeep-health-care]

The Role of Artificial Intelligence in Early Cancer Diagnosis

Improving the proportion of patients diagnosed with early-stage cancer is a key priority of the World Health Organisation. In many tumour groups, screening programmes have led to improvements in survival, but patient selection and risk stratification are key challenges. In addition, there are concerns about limited diagnostic workforces, particularly in light of the COVID-19 pandemic, placing a strain on pathology and radiology services. In this review, we discuss how artificial intelligence algorithms could assist clinicians in (1) screening asymptomatic patients at risk of cancer, (2) investigating and triaging symptomatic patients, and (3) more effectively diagnosing cancer recurrence. We provide an overview of the main artificial intelligence approaches, including historical models such as logistic regression, as well as deep learning and neural networks, and highlight their early diagnosis applications. Many data types are suitable for computational analysis, including electronic healthcare records, diagnostic images, pathology slides and peripheral blood, and we provide examples of how these data can be utilised to diagnose cancer. We also discuss the potential clinical implications for artificial intelligence algorithms, including an overview of models currently used in clinical practice. Finally, we discuss the potential limitations and pitfalls, including ethical concerns, resource demands, data security and reporting standards.

1. Introduction

Early cancer diagnosis and artificial intelligence (AI) are rapidly evolving fields with important areas of convergence. In the United Kingdom, national registry data suggest that cancer stage is closely correlated with 1-year cancer mortality, with incremental declines in outcome per stage increase for some subtypes [1]. Using lung cancer as an example, 5-year survival rates following resection of stage I disease are in the range of 70–90%; however, rates overall are currently 19% for women and 13.8% for men [2]. In 2018, the proportion of patients diagnosed with early-stage (I or II) cancer in England was 44.3%, with proportions lower than 30% for lung, gastric, pancreatic, oesophageal and oropharyngeal cancers [3]. A national priority to improve early diagnosis rates to 75% by 2028 was outlined in the National Health Service (NHS) long-term plan [4]. Internationally, early diagnosis is recognised as a key priority by a number of organisations, including the World Health Organisation (WHO) and the International Alliance for Cancer Early Detection (ACED).

Many studies indicate that screening can improve early cancer detection and mortality, but even in disease groups with established screening programmes such as breast cancer, there are ongoing debates surrounding patient selection and risk–benefit trade-offs, and concerns have been raised about a perceived ‘one size fits all’ approach incongruous with the aims of personalised medicine [5,6,7]. Patient selection and risk stratification are key challenges for screening programmes. AI algorithms, which can process vast amounts of multi-modal data to identify otherwise difficult-to-detect signals, may have a role in improving this process in the near future [8,9,10]. Moreover, AI has the potential to directly facilitate cancer diagnosis by triggering investigation or referral in screened individuals according to clinical parameters, and automating clinical workflows where capacity is limited [11]. In this review, we discuss the potential applications of AI for early cancer diagnosis in symptomatic and asymptomatic patients, focussing on the types of data that can be used and the clinical areas most likely to see impacts in the near future.

2. An Overview of Artificial Intelligence in Oncology

2.1. Definitions and Model Architectures

AI is an umbrella term describing the mimicking of human intelligence by computers (Figure 1). Machine learning (ML), a subdivision of AI, refers to training computer algorithms to make predictions based on experience, and can be broadly divided into supervised (where the computer is allowed to see the outcome data) or unsupervised (no outcome data are provided) learning. Both approaches look for data patterns to allow outcome predictions, such as the presence or absence of cancer, survival rates or risk groups. When analysing unstructured clinical data, an often-utilised technique, both in oncology and more broadly, is natural language processing (NLP) [12]. NLP transforms unstructured free-text into a computer-analysable format, allowing the automation of resource-intensive tasks.

It is common practice in ML to split data into partitions, so that models are developed and optimised on training and validation subsets, but evaluated on an unseen test set to avoid over-optimism. A summary of commonly used supervised learning methods is provided in Table 1. Such methods include traditional statistical models such as logistic regression (LR) as well as novel decision tree and DL algorithms.

Deep learning (DL) is a subgroup of ML, whereby complex architectures analogous to the interconnected neurons of the human brain are constructed. Popular Python-based frameworks for deep learning include Tensorflow (Google) and PyTorch (Facebook), which provide features for model development, training and evaluation. Google also provides a free online notebook environment, Google Colaboratory, allowing cloud-based Python use and access to graphic processing units (GPUs) without local software installation.

Although a detailed description of neural network structures is beyond the scope of this article, artificial neural networks (ANNs) can be used to illustrate the overarching principles (Figure 2). As a recent example, Muhammad et al. used an ANN to predict pancreatic cancer risk using clinical parameters such as age, smoking status, alcohol use and ethnicity [18]. In their most basic form, ANNs consist of: (1) an input layer, (2) a ‘hidden layer’, consisting of multiple nodes which multiply the input by weights and add a bias value, and (3) the output layer, passing the weighted sum of hidden layer nodes to an activation function to make predictions. Deep learning simply refers to networks with more than one hidden layer.

Figure 2. Example of a single-hidden-layer ANN architecture. (1) The smoking status in pack years and lung nodule size (mm) are entered as the two input nodes. (2) In the hidden layer, each node multiplies the values from incoming neurons by a weight (shown as decimals at incoming neurons) and aggregates them. (3) The results are passed to an activation function, converting the output to a probability of cancer between 0 and 1. Multiple learning cycles are used to update the hidden layer weights to improve performance.

Many early diagnosis models have exploited convolutional neural network (CNN) architectures, which led to a revolution in computer-vision research by allowing the use of colour images as input data. While the downstream fully connected layers resemble those of an ANN, the input data are processed by a series of kernels which slide over image colour channels and extract features, such as edges and colour gradients. These inputs are then pooled and flattened before being passed to the fully connected layer. Many pre-defined CNN architectures with varying degrees of complexity are available for use, including AlexNet [20], EfficientNet [21], InceptionNet [22], ResNet [23] and DenseNet [24]. As we discuss further in this article, CNNs have a wide range of applications in radiology and digital pathology.

2.2. Data Types: Electronic Healthcare Records

A number of emerging healthcare data modalities are suitable for analysis with AI. In recent years, a global expansion in electronic healthcare record (EHR) infrastructures has occurred, enabling vast amounts of clinical data to be stored and accessed efficiently [25]. Many exciting digital collaborations are arising to facilitate early diagnosis research using EHRs, including the UK-wide DATA-CAN hub [26]. Other digital databases record outcome measures and pathway data. For example, the Digital Cancer Waiting Times Database aims to improve cancer referral pathways through user-uploaded performance metrics [27].

It is important to draw a distinction between local hospital EHR data and national public health data registries, including those utilised by multi-centre screening studies. With registries, unified database structures are being implemented for consistency across institutions. A key aim of the NHSx ‘digital transformation of screening’ programme is to ensure interoperability of systems, so that data can flow seamlessly along the entire screening pathway, including into national registry databases [28]. An example of database unification is the new U.K. cervical cancer screening management system, which will simplify 84 different databases into a single national database, and aims to streamline data entry and provide simple, cloud-based access for users [29].

Digital databases, whether local or national, are ripe for analysis with AI, which is inherently able to process large amounts of information (‘Big Data’) [30]. EHR data typically include structured, easily quantifiable data such as admission dates or blood results, and unstructured free-text such as clinical notes or diagnostic reports. The latter can be analysed using NLP approaches. An overview of NLP in oncology is provided by Yim et al. [12], and example early diagnosis uses include identifying abnormal cancer screening results [31], auditing colonoscopy or cystoscopy standards [32,33] and identifying or risk-stratifying pre-malignant lesions [34,35,36,37,38]. NLP has also been used to automate patient identification for clinical trials, reducing the burden of eligibility checks [39]. Morin and colleagues published an exciting example of how AI and NLP technology can integrate into EHR systems: their model can analyse millions of data points and perform real-time cancer prognostication based on continuous learning of routinely collected clinical data

Read More: https://www.europeanhhm.com/articles/the-role-of-artificial-intelligence-in-early-cancer-diagnosis

[market-insider]

Biomarker Testing Services: Transforming Healthcare Delivery and Patient Outcomes

The global biomarker testing services market size is expected to reach USD 1,399.4 million by 2030. Growing investment in pharmaceutical R&D, increasing demand for the precision medicine used for cancer treatment, and growing burden of the infectious and chronic diseases facilitating the demand for the biomarker testing are some of the major factors driving the market's growth.

Gain deeper insights on the market and receive your free copy with TOC now @: Biomarker Testing Services Market Report Report

There has been a consistent rise in clinical trials during the last 5 years. For instance, according to ClinicalTrials.gov, more than 262,298 trials were registered in 2018, whereas as of September 2022, above 399,518 trials were registered. Clinical trials are expected to improve in the coming years owing to the increase in funding for clinical research. This is expected to boost demand for medicine discovery research activities and thus support demand for biomarker testing in the post-pandemic period.

The FDA approval rate for medicines through the use of biomarkers has improved, over the years. For instance, in 2016, more than 26 trials were approved by the FDA that used biomarkers for medicine testing, whereas, in 2019, 36 trials were approved by the FDA that used biomarkers for medical testing. Clinical trials now require biomarker-related data for medicine approvals, as it provides information about the action of medicine in the body and thus speeds up the medicine approval process. This is expected to improve demand for biomarker testing during the forecast period.

Various biopharmaceutical companies are taking initiatives to improve the diagnosis rate of the cancer patient through biomarker testing. For instance, in April 2021, a biopharmaceutical company, Amgen launched the Biomarker Assist Program. As per this program, patients with metastatic (stage IV) non-small cell lung cancer (NSCLC) were provided biomarker testing, to check the presence of oncogene biomarkers, which help in targeted therapies. Such initiatives by the market players are likely to support the market's growth.

According to the IQVIA, report on oncology trends, clinical trials for cancer have been increasing for the last 10 years. For instance, in 2011, 1,242 trials were registered for cancer, and as of 2021, 2,335 trials were registered for cancer. The number of clinical trials intended for cancer is expected to rise even further owing to the growing prevalence of the disease. There is an increasing demand for targeted therapies designed for cancer that use biomarkers for testing the efficacy of the drug in the research. Increased cancer research in the coming years is expected to boost demand for the biomarkers designed for cancer testing and thus support the market in the post-pandemic period.

[phawareglobal]

Rosemary Graham - phaware® interview 405

Pulmonary hypertension and lupus patient, Rosemary Graham details her 39 year history navigating multiple rare disorders and  the importance of her faith, self-care and never giving up. My name is Rosemary Graham. I live in Atlanta, Georgia. I have been diagnosed with pulmonary hypertension since 2012. Before that, I was diagnosed with lupus and interstitial lung disease in 1984. Then, in 1985 was diagnosis with polymyositis or myositis, which they're now terming as lupus myositis. I am acquainted with the pulmonary hypertension group because I am a patient. I had a right heart catheterization done last year and my numbers were back up to stage 3. 

In terms of how I got pulmonary hypertension, it was around Christmastime and I had gone to see my rheumatologist. I wasn't feeling good that day. I knew something wasn't right. My breathing was off and everything was off that day and I was slightly dizzy. He and I used to joke around with each other and he listened to my heart and all of a sudden he had a puzzled look on his face. So he checked to the back. He went to the front. He went to the back. He went to the front again. He went to the back again, checking my heart and lungs and chest and everything. When he sat down, he started typing and he looked up at me and he said, "Either you have congestive heart failure or you might have pulmonary hypertension. I need for you when you leave this office, to contact your cardiologist and contact your pulmonologist as soon as possible." Walking to the car, I was calling the pulmonologist's office. I had an appointment the following week. They did a stress test. They did several tests. My pulmonologist came in and I did not know but he was also a pulmonary hypertension specialist. He did a right heart catheterization. I was at stage 3 with pulmonary hypertension.

He immediately put me on medication. I had to increase my oxygen flow. I had to increase my oxygen level up to 8 liters. I have had a myriad of problems. I would say right now probably about between 10 and 11 disorders, everything flowing back to lupus. The pulmonary hypertension came about because of the pulmonary fibrosis or it came from the lupus. The pulmonary fibrosis came from the lupus with interstitial lung disease. My lupus however, is in remission. Praise God, for right now. 

This month marks the beginning of my diagnosis of lupus in February 39 years ago. I had bronchitis to two months where I'd had nothing till a diagnosis of double pneumonia. Then, from double pneumonia I did not get better. I ended up with the diagnosis of lupus and interstitial lung disease. So I have been dealing with chronic illnesses for 39 years.

I've also had cancer. I was diagnosed with endometrial cancer in 2017. I had surgery in January of 2018. It was stage 1, grade 1. The surgery only took maybe less than two hours, but I ended up in ICU after that because of the oxygen and my blood pressure and there was something else that was going down fast. But I knew that I would end up in ICU. I have a friend who is one of my church members who's a nurse that actually worked at that hospital. She was able to get off that day and be with me. So she was watching them do the surgery. She helped me get undressed to prepare me for the surgery. Then when the doctor came and told my cousin and her that they had put me in ICU, she'd take out her badge and she came into the ICU unit just checking to make sure that everything was going okay.

I am single. I am not married. I do not have any children. My parents are deceased. My dad died in '85. My mother died in 2005. I don't have any siblings. All of my aunts and uncles are gone. So now it's just the cousins. So it’s me taking care of me and Jesus. It's Jesus taking care of me. It has been a long road. I have had many blessings, even in spite of what's going on. But in the beginning when I was diagnosed with lupus, I dealt with clinical depression. I am taking an antidepressant right now because I have been dealing with depression. The emotional effects of having a chronic illness for 39 years is now starting to wear on me a little bit in terms of taking medications and seeing doctors and going for lab tests, having blood drawn, but it has also been a blessing.

I was involved in a disability ministry for 24 years. I just retired. I was doing that part-time, working with pastors and leaders on the needs of people with disabilities. It's been a challenge. It has been a challenge. There are days I only allow myself a couple of minutes or a couple of days to be in the pit, but now I challenge myself. I read scripture, listen to inspirational music, look at inspirational videos or listening to sermons or motivational speeches or anything that will uplift me in a very certain way. For those of us that are dealing with rare disorders, I think it's even more of a challenge because of the medications we have to take because of the side effects that come along with those medications. Also, the uncertainty of the disease and whether or not it's progressive and what stage are you in. Even in terms of how you get your rest, your energy levels in terms of how much you get engaged in society, in terms of how much you engage with your family. Whether or not you and most importantly, you taking care of you is the most important thing. Self-care for a patient with rare disorders is a must. 

I have gone through that where my self-care was not good and I was depressed. You may or may not know, depression can cause pain and inflammation and pain and inflammation can cause depression. Finding ways to overcome that, finding ways to step away from that and look for a glimmer, a spark, is what I reach for or grab for. I'm probably sure the other people that have pulmonary hypertension could say the exact same thing. You have to have something that will keep you going. 

I would say don't give up. I can actually hear somebody saying that's what you're saying, but I feel like I can't take no more. I've seen that. I've heard that, I've said that several times. God, I can't take no more. But somewhere in the midst of that though, and that's why I say, you have to have a foundation that can hold you up when you get that low. My faith really did help me. Whether or not you are a Christian or not, you have to have something, a foundation. When you get that low you can say no, there's still something left that I can do. 

When I was diagnosed with lupus and I lost my job, I lost my apartment. I lost a lot of things when I was diagnosed with lupus in '84. I did not know what I was going to do. Because I was connected to a church, the pastor and the members helped me find a house and the pastor actually said, "You know, we don't have a church secretary, so why don't you be our church secretary?" That's where I had a little money coming in. I did go and get all my resources I possibly could until the Lord opened up the door for me to start working as a regional disability ministry director.

I also got involved with the Lupus Foundation. I was a volunteer. I did everything from health fairs to talking to businesses and corporations about lupus. I ended up on the Board of Directors of the Lupus Foundation. I ended up on the Board of Directors for the National Black Women's Health Project. I ended up on the Board of Directors for the Black Women's Health Studies that is still going on between Boston and Howard Universities. I ended up on an advisory committee with Jimmy Carter back in the day. So I became very active in spite of the challenges. We say there is life after lupus so I would say to my friends that there is life after PH. There's life after that. But I will not in any way negate the hardness, the absolute sometimes horror of this disease and other diseases like this that are rare that can take us down quick. 

My name is Rosemary Graham and I am aware that I'm rare. Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Follow us on social @phaware Engage for a cure: www.phaware.global/donate  #phaware Share your story: info@phaware.com

Listen and View more on the official phaware™ podcast site

[cyarskj1899]

Toggle navigation

FOLLOW LOVEBSCOTT

Sponsored Content

A Teaspoon On An Empty Stomach Burns 12 Lbs Of Fat A Week Safely!

Keto

Non Small Cell Lung Cancer Signs You Might Be Ignoring

Search Ads

What Causes Runny Nose Is Not What You Think. Check Home Remedies

Search Ads

Home

News

NEWS

Walker

Ella Mai Will Bring Her ‘Heart On My Sleeve’ Album On A North American Tour

January 25, 2023 6:17 AM PST

Ella Mai announced that she would be going on tour in 2023. 

via: Rap-Up

The R&B singer has announced dates for her “Heart on My Sleeve” tour. The 34-date trek kicks off March 31 in Wallingford, Conn. and travels across North America, with stops in New York, Atlanta, Miami, and Los Angeles, wrapping June 1 in Toronto.

The tour comes in support of her latest album Heart on My Sleeve, which was released in May. A deluxe edition is set for release on Feb. 2.

“The deluxe tracks are some of my favorite songs currently so I’m happy to be able to share them with the world,” said Ella. “I get to bring new life to a body of work that is a year old but remains very close to my heart. Likewise with the Heart On My Sleeve Tour. This is the first time I’m getting to perform some of these tracks live. It’s almost like reading your diary aloud in front of an audience, but there’s no better place for me to be vulnerable than in my music and on stage with my fans.”

This will be Ella’s third headlining tour since 2018. She most recently joined Mary J. Blige on her “Good Morning Gorgeous Tour” last fall.

Tickets go on sale Jan. 27 at 10 a.m. local time, with a pre-sale starting Jan. 25. See dates below.

Heart on My Sleeve Tour Dates

Mar. 31 – Wallingford, CT – The Dome at Oakdale Theatre Apr. 2 – Providence, RI – The Strand Theatre Apr. 3 – Philadelphia, PA – Franklin Music Hall Apr. 4 – New York, NY – Terminal 5 Apr. 6 – Boston, MA – House of Blues Apr. 8 – Washington, DC – Echostage Apr. 10 – Atlanta, GA – Coca-Cola Roxy Apr. 12 – Miami, FL – Revolution Live Apr. 13 – Orlando, FL – House of Blues Apr. 18 – Raleigh, NC – The Ritz Apr. 19 – Baltimore, MD – Rams Head Live! Apr. 21 – Richmond, VA – The National Apr. 22 – Norfolk, VA – The NorVa Apr. 24 – Nashville, TN – Marathon Music Works Apr. 25 – Charlotte, NC – The Fillmore Apr. 27 – New Orleans, LA – The Joy Theater Apr. 30 – Dallas, TX – House of Blues May 1 – Houston, TX – Warehouse Live May 4 – Tempe, AZ – Marquee Theatre May 5 – San Diego, CA – SOMA May 7 – Los Angeles, CA – The Novo May 13 – Seattle, WA – The Showbox May 14 – Portland, OR – Crystal Ballroom May 15 – Vancouver, BC – Harbour Event & Convention May 17 – Salt Lake City, UT – The Depot May 18 – Las Vegas, NV – House of Blues May 20 – Denver, CO – Ogden Theatre May 22 – Minneapolis, MN – The Fillmore May 24 – Chicago, IL – House of Blues May 25 – Indianapolis, IN – Egyptian Room at Old National Centre May 27 – Cincinnati, OH – Bogart’s May 28 – Columbus, OH – Newport Music Hall May 30 – Detroit, MI – Saint Andrew’s Hall June 1 – Toronto, ON – HISTORY

Share This Post

Around The Web

2 Cards Charging 0% Interest Until 2024

CompareCredit.com

Add This to Your Dinner Everyday if Your over 45

Dr. Kellyann

Doctors Stunned: This Removes Wrinkles Like Crazy (Try Tonight)

Skincare Update

Toenail Fungus? Use This 3-minute Shower Hack to Flush It Away in Seconds

Kerassentials

Wrap Your Car Keys in Foil at Night when Alone, Here's Why

Sogoodly

Average Travel Nursing Salary in 2023 is Just Unbelievable (See The List)

Travel Nurse | Sponsored

The #1 Mistake That Makes Bad Knees Worse (Watch)

Arthrozene

Doctors Stunned: Home Remedy "Fixes" E.D. Like Crazy! Do This

Try it tonight!

This Simple Evening Ritual Burns Belly Fat Like Crazy! (Try Tonight)

Living Healthy News

SPONSORED CONTENT

Kellogg partners with farmers to reduce GHG emissions

By Kellogg

Tags:Ella Mai

© LOVEBSCOTT 2020 

Sent from my iPhone

[cavixorg]

A biopharmaceutical firm in the clinical stages called Kintara Therapeutics, Inc. is dedicated to the creation and marketing of innovative cancer treatments. With a focused on orphan cancer indications, the company is creating and marketing anti-cancer treatments for people whose solid tumors display characteristics that make patients resistant to or unlikely to react to existing therapies. The two leading possibilities for the company are VAL-083 and REM-001. Its VAL-083 is a brand-new, approved deoxyribonucleic acid (DNA) targeted agent for the treatment of narcotic solid malignancies such diffuse intrinsic pontine glioma, glioblastoma multiforme. And maybe other solid tumors like ovarian cancer and non-small cell lung cancer (DIPG) REM-001, a delayed photodynamic therapy (PDT) product from the company, is used to treat cutaneous metastatic breast cancer (CMBC). About Kintara Additionally, Kintara offers a unique, late-stage PDT technology that shows promise for treating localized visceral or cutaneous tumors as well as for other possible purposes. People with CMBC who had previously had chemotherapy and/or unsuccessful radiation therapy were enrolled in four Phase 2/3 drug testing to examine the effects of REM-001 therapy. The clinical efficacy of REM-001 in CMBC is currently 80% full remission of CMBC evaluable lesions, and there is a strong safety database of almost 1,100 patients across several indications. To save money, Kintara has suspended the REM-001 CMBC initiative. Who Founded Kintara? The company was established in 2010 and has its headquarters in Canada's Vancouver. We can list its founders as Dennis M. Brown, Jeffrey A. Bacha, Jeffrey Bacha. Since November 8, 2021, Robert E. Hoffman has served as president and chief executive officer, board chairman since June 2018, and director since April 2018. Inc. Aslan Pharmaceuticals He participates inside the Board of Directors as a member. Since October 2018, he has been on the board of directors. Since November 2020, he has also sat on the board of Antibe Therapeutics Inc., where he has served as chairman since May 2022. Editas Medicine, Fulcrum Therapeutics, or Semma Therapeutics are probable rivals and alternatives to Kintara Therapeutics. There are three investors in Kintara Therapeutics, including the Luxembourg National Research Fund and Lincoln Park Capital Fund. What Are Kintara's Academic Collaborations? University of Texas MD Anderson Cancer Center: The goal of Kintara Therapeutics' partnership with MDACC is to investigate how DNA damage response (DDR) pathways affect VAL-083's ability to kill ovarian cancer cells and the potential for combining it with other therapies like PARP inhibitors. University of California San Francisco: By speeding the development of this much needed new medication for GBM, UCSF played a crucial role in expanding patient access and serving as the primary clinical location for our initial clinical trial. UCSF is also testing VAL-083's efficacy versus pediatric elevated glioma and medulloblastoma subtypes, both as a single drug and in combination with other therapies. British Columbia University: The collaboration between Kintara Therapeutics and the University of British Columbia is focused on investigating the DNA repair response (DDR) to VAL-083 therapies in a variety of pediatric brain cancer subgroups (personalized drug treatment) and assessing the potential for topoisomerase inhibitor-combined therapies. Highlights Of The Company And Recent Developments a statement stating that three posters had been approved for presentation of data at the Society for Neuro-Oncology (SNO) Annual Conference in 2022. The 2022 SNO Annual Session will be held in Tampa, Florida, from November 16 to November 20, 2022. (September). Robert E. Hoffman, president and chief executive officer of Kintara, said, "We have focused our VAL-083 program in glioblastoma sufferers and are looking forward to reporting top-line findings in the worldwide registrational GBM AGILE Study before the end of 2023."

"We believe VAL-083 may be an extra tool to help this neglected condition," the statement reads. "GBM patients and clinicians are in need of more medicines to tackle this fatal disease." A Report On The Financial Results For The 2023 Fiscal Year Kintara had about $7.1 million in cash and equivalents as of September 30, 2022. For a net profit to the company of almost $1.9 million during the three months ending September 30, 2022, Kintara concluded the sale of ordinary KTRA stock under a sales contract with Lincoln Park. Kintara reported a net loss of about $4.6 million, or $0.07 per share, for the three months that ended on September 30, 2022, compared to a net loss of about $6.0 million. Or $0.25 per share, for the three months that ended on September 30, 2021. Reduced research and development costs as well as lower expenses for general and administrative were the main causes of the lower net loss for the three months that ended September 30, 2022 as compared to the three months ending September 30, 2021. Kintara Therapeutics Stock Purchase Procedure Pick a location to purchase Kintara Therapeutics shares. Selecting a stock brokerage is necessary. Open a trading account. Enroll in 0% commission betting with the top brokerage we could find. The greatest location to get KTRA stock is there. Your brokerage account with the money. Add your details and choose your payment method. Analyze the stock of Kintara Therapeutics. The ticker symbol for Kintara Therapeutics is KTRA. Complete the KTRA transaction. Choose whether to buy KTRA stock using a limit order to acquire it at a specific price or at the current market rate. Get up-to-date information on your KTRA investment. Make a watchlist of important updates about your Kintara Therapeutics stock investment. Is This A Good Time To Purchase Shares Of Kintara Therapeutics? The average analyst rating for Kintara Therapeutics among the three Wall Street analysts who follow KTRA is "Hold." On September 29, 2022, Jason McCarthy, a Maxim Group bottom 2% analyst, downgrades KTRA to a hold rating. On May 16, 2022, Jason Kolbert, a Dawson James bottom 7% analyst, downgrades KTRA to a hold rating. On January 20, 2022, Michael King, a bottom 7% analyst at HC Wainwright & Co., keeps KTRA with a buy recommendation but decreases their price objective from $6.00 to $3.00.   Kintara Declares A Reverse One-For-Fifty Stock Split The 1-for-50 reverse KTRA stock split of Kintara's authorized and outstanding common stock will take effect at 5:00 p.m. (EST) on November 11, 2022. Kintara is a biopharmaceutical firm that focuses on the development of innovative solid tumor cancer medicines. The Nasdaq Capital Market will continue to list Kintara's common shares under the ticker "KTRA" and a new CUSIP code, 49720K200. On November 14, 2022, when the market opens, Kintara's common stock will start trading on The Nasdaq Capital Market on a reverse stock divide basis. In order to continue being listed on The Nasdaq Capital Market, Kintara's common stock must trade at a minimum bid price of $1.00 per share, which will be met by the reverse stock split (Nasdaq Listing Rule 5550(a)(2)). Every fifty pre-split shares of ordinary shares that are now outstanding and authorized will be automatically combined into one new share of common stock as a result of the reverse stock split without even any action on the part of the stockholders. Number Of Authorized Shares Of Stocks There will be around 1,616,146 outstanding and issued shares of stockholders as opposed to the 80,807,316 that were granted and current as of November 8, 2022. There will be a drop in the authorized common stock shares from 275,000,000 to 5,500,000. In accordance with the reversal stock split, no mutual funds will be distributed. No stockholders will receive money in lieu of fractional shares as a result of the reverse stock split; rather, any preferred stock of common stock will be rounded up to the closest whole post-split sh

are. The criminal records, vesting units, and stock options of Kintara will also be subject to the reverse stock split, with the conversion and exercise prices thereof being adjusted in accordance with the terms of those securities. The backward stock split will also apply to common shares issuable upon the converting of Kintara's outstanding company stock. What Is The Current Value Of Kintara Stock? KTRA (NASDAQ: ) There are 1,616,146 shares of Kintara Therapeutics outstanding at the moment. The market capitalization of Kintara Therapeutics stock, which is currently trading at $4.43 per share, is $7.05M. On February 22, 2013, Kintara Therapeutics stock went public at a price of $3,400.00. Your return over the past nine years if you had purchased Kintara Therapeutics stock at $3,400.00 would also be -99.87%, for an annualized return of -52.28%. Due Diligence Examines According to our assessment of its fair market value cost of $16.45 depending on discounted cash (DCF) modeling, KTRA ($4.43) is overvalued by 73.5%, but it does not have a substantial margin of safety.  According to our assessment of KTRA's fair value cost of $16.45 based on discounted cash (DCF) modeling, which includes a strong margin of safety, the KTRA stock is currently markedly undervalued at $4.43, a difference of 73.5%. We cannot determine KTRA's intrinsic value using a revised list of Benjamin Graham's method from "The Intelligent Investor" since KTRA is not profitable. In three years, KTRA's Return on Equity is expected to be strong (24.87%); analysts are optimistic about the company's capacity to effectively create return on equity. In comparison to the US Biotechnology sector average (12.5%), KTRA stock forecast is predicted to produce a better Return on Assets (18.11%). The Return on Equity (-193%) of KTRA demonstrates a business that is ineffective at converting shareholders ’ equity into returns. The US Biotechnology sector average (2.32%) is higher than KTRA's Return on Assets (-145.2%). When compared to three years ago (-109.07%), KTRA's capacity to produce Return on Capital has reduced (-220.17%). What Is The Target Price For Kintara? The average KTRA price goal is $3.00, with the top and cheapest KTRA stock forecast both coming in at $3.00, according to one Wall Street analyst who has published a KTRA price target for the next year. By September 29, 2023, the Wall Street analyst projected that Kintara Therapeutics' share price may reach $3.00. From the present KTRA share price of $4.36, the consensus Kintara Therapeutics stock price projection predicts a potential decline of 31.19%. Kintara Therapeutics Stock Price Forecast For 2023 At the time of writing, one share of KTRA stock costs roughly $4.43. Kintara Therapeutics' stock has 3 1 year target prices from Wall Street analysts. Their predictions for the price of KTRA stock forecast range from $150 to $150. They anticipate that within a year, the actual share price will rise to $150. This represents a potential increase from of the stock's market valuation of 3,380.3%. From the most recent price of 4.50, the consensus KTRA stock forecast reflects a +3,182.28% rise. Currently, there is agreement among the two investment analysts that were surveyed to hold Kintara Therapeutics Inc. shares. Until September, when it stayed constant from a hold rating, this rating has remained stable. KTRA Stock Forecast 2024 The revenue for Kintara Therapeutics in 2022 is zero. With the lowest KTRA stock forecast at $31,741,107 and the highest KTRA stock forecast at $31,741,107, 1 Wall Street analysts expect KTRA's revenue will be $31,741,107 on average in 2023. With the lowest KTRA stock forecast coming in at $146,956,156 and the highest KTRA stock forecast coming in at $146,956,156, 1 Wall Street analysts expect KTRA to generate $146,956,156 in revenue in 2024 on average. KTRA Stock Forecast 2025 The revenue for Kintara Therapeutics in 2022 is -$21,661,000. With the cheapest

KTRA stock forecast prognosis being $48,484 and the greatest KTRA earnings projection being $48,484, 1 Wall Street analyst estimated KTRA's earnings to be $48,484 on average for 2023. KTRA stock forecast are expected to be $905,042 on average in 2024, according to one Wall Street analyst, with the lowest and highest estimates both being $905,042. KTRA stock forecast to earn $2,391,896 in 2025, with the lowest and greatest estimates of earnings both coming in at $2,391,896. KTRA is anticipated to create $362,016,704 in revenue in 2025, with $362,016,704 as the lowest and $362,016,704 as the highest revenue projections. Paying dividends is not a source of income for Kintara Therapeutics.